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Staphylococcus aureus (SA) is usually present not only in the skin lesions of atopic dermatitis (AD) but also in the atopic dry skin. SA discharges various 
toxins and enzymes that injure the skin, results in activation of epidermal keratinocytes, which produce and release IL-18. IL-18 that induces the super 
Th1 cells secreting IFN-g and IL-13 is supposed to be involved in development of AD and its pathogenesis. Indeed, the number of SA colonies on the skin 
surface and the serum IL-18 levels in patients with AD significantly correlated with the skin scores of AD lesions. Also, there is strong positive correlation 
between the skin scores and serum IL-18 levels in DS-Nh mice (P<0.0001, r=0.64), which develop considerable AD-like legions when they are housed un-
der conventional conditions, but develop skin legions with less severity and less frequency under specific pathogens free (SPF) conditions. Therefore, they 
are well-known as model mice of AD, in which SA is presumed to be critical factor for the development of AD lesions. Also, theses DS-Nh mice pretreat-
ed with Cy developed more remarkable AD-like lesions in comparison with non-treated ones. The levels of INF-r and IL-13 in the supernatants of the 
lymph node cell cultures stimulated with staphylococcal enterotoxin B (SEB) or ConA were increased in the Cy-treated mice, although the serum levels of 
total IgE were not. In this experiment, we revealed that Cy-treated mice, to which CD25 +CD4 + reguratory T cells taken from non-treated ones had been 
transferred, developed the AD-like legions with less severity and less number of SA colonies on the skin surface. Therefore, it is presumed that CD25 
+CD4 + reguratory T cells might be involved in the suppression of super Th1 cells which are induced by IL-18 and are involved in the development of AD-
like lesions rather than IgE production. The efficient induction of CD25 +CD4 + reguratory T cells is expected for the new type of treatment of AD. We also 
found that farnesol (F) and xylitol (X) synergistically inhibited biofilm formation by SA, and indeed the ratio of SA in total bacteria at sites to which the FX 
cream containing F and X had been applied was significantly decreased 1 week later, accompanied with improvement of AD, when compared with that 
before application and at placebo sites. Therefore, the FX cream is a useful skin-care agent for atopic dry skin colonized by SA. The nerve growth factor 
(NGF) in the horny layer (the horn NGF) of skin lesions on the cubital fossa was collected by tape stripping and measured using ELISA in AD patients be-
fore and after 2 and 4 weeks treatments. Simultaneously, the itch and eruptions on the whole body and on the lesions, in which the horn NGF was mea-
sured, were recorded, and also the peripheral blood eosinophil count, serum LDH level and serum total IgE level were examined. The level of NGF was 
significantly higher in AD patients than in healthy controls, correlated with the severity of itch, erythema, scale/xerosis, the eosinophil count and LDH lev-
el, and also significantly decreased after treatments with olopatadine and/or steroid ointment for 2 and 4 weeks. Therefore, the measurement of the NGF 
by this harmless method seems to be useful to assess the severity of AD and the therapeutic effects on AD. In AD patients, C-fiber in the epidermis in-
crease and sprout, inducing hypersensitivity, which is considered to aggravate the disease. Semaphorin 3A (Sema3A), an axon guidance molecule, is a 
potent inhibitor of neurite outgrowth of sensory neurons. We administered recombinant Sema3A intracutaneously into the skin lesions of NC/Nga mice, 
an animal model of AD, and investigated the effect of Sema3A on the skin lesions and their itch. Sema3A dose-dependently improved skin lesions and 
attenuated the scratching behavior in NC/Nga mice. Histological examinations revealed a decrease in the epidermal thickness, the density of invasive 
nerve fibers in the epidermis, inflammatory infiltrate including mast cells 
and CD4 +T cells, and the production of IL-4 in the Sema3A-treated le-
sions. Because the interruption of the itch-scratch cycle likely contributes 
to the improvement of the AD-like lesions, Sema3A is expected to become 
a promising treatment of patients with refractory AD. 
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INTRODUCTION 
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory 
skin disease characterized by highly pruritic, eczematous skin 
lesions. Various factors including the immunological and non-
immunological abnormalities contribute to the pathogenesis 
and development of AD. Patients with AD generally have a fa-
milial predisposition of increasing in serum IgE antibodies to 
various allergens and development of eczematous skin lesions 
as the immunological abnormalities. On the other hand, physi-
ological barrier dysfunctions of the skin, high detection of Staph-
ylococcus aureus (SA) in the bacterial flora on their skin surface 
flora and an increased hypersensitivity to itch are known as the 
non-immunological abnormalities. In this paper, we would like 
to review the recent papers concerning the pathogenesis and 
biomarker of AD and its itch and to discuss a probable role of 
SA, interleukin-18 (IL-18), nerve growth factor (NGF) and 
semaphorin 3A (Sema3A) of an axon guidance molecule in 
pathogenesis and treatment of AD. 
A PROBABLE ROLE OF STAPHYLOCOCCUS AUREUS (SA) 
AND INTERLEUKIN-18 (IL-18) IN PATHOGENESIS AND 
BIOMARKER OF AD
Recently, we measured the conductance and transepidermal 
water loss (TEWL) on the medical examination of infant. In or-
der to examine their usefulness for early diagnosis of AD and 
reveal that the TEWL in the uninvolved skin of abdomen signifi-
cantly increased in infants with AD already as early as 6 months 
and 1.5 years old, when compared with that in infants without 
AD. Therefore, the measurement of TEWL in the skin is useful 
for early diagnosis of infantile AD and the early care on the skin 
of these infants might be expected to effect protectively on de-
velopment and aggravation of AD.
1 We have already reported 
that Staphylococcus aureus (SA) usually existed not only on the 
skin regions affected by AD but also on the atopic dry skin re-
gions.
2 The number of SA detected on the skin surface of forearm 
and forehead in AD patients was remarkably more than that in 
healthy controls, as shown Fig. 1.
2 There was a significant correla-
tion between eruption score and the number of SA detected on 
the same area of patients with AD (relationship coefficien-
cy=0.54, P<0.01),
1 as shown in Fig. 2.
3 We have also reported 
that farnesol (F) of a perfume and xylitol (X) of sugar alcohol 
synergistically can inhibit the biofilm formation of SA and 
moreover can dissolve the formed biofilm of SA, as shown in 
Fig. 3-1 and Fig. 3-2.
3,4 Indeed, the treatment with FX cream im-
proved significantly 4 out of 5 items in AD lesions at 2 weeks lat-
er, while the treatment with control cream improved only 1 
item of dryness/desquamation as shown in Fig. 4.
3,4 Both of the 
number of SA and the ratio of SA to total bacteria at the sites, to 
which the FX cream containing F and X had been applied, sig-
nificantly decreased in 2 weeks later, accompanied with clinical 
improvement of AD, as shown in Fig. 5.
3,4 The therapeutic effect 
of this FX cream is conceivable to be based on two functions of 
: the distribution of total bacteria number and 
: the mean total bacteria number in 45 patients with AD
: the mean range of total bacteria and SA number in healthy controls
: the distribution of SA number and 
: the mean SA number in 45 patients with AD
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Fig. 1. The number of SA detected on the skin surface of forearm and forehead in patients with AD is remarkably more than in healthy controls.
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Fig. 2. The correlation between eruption score and the number of SA on the same area of patients with AD.
3  cfu: colony forming unit.
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Fig. 3-1. Farnesol and xylitol (FX) have an inhibitory effect on biofilm formation of SA.
3 A biofilm of bacteria was formed by incubating a plastic coverslip coated with 
type IV collagen in each well of a 24-well tissue culture plate with the human plasma and TSB (1:1) medium, into which SA was inoculated. Cell suspensions of SA 
from an AD patient (1x10
8 cfu/mL) were inoculated separately into 1 mL of the medium either alone (control) or supplemented with FX. After incubation at 37℃, 
each coverslip was observed visually and also under a scanning electron microscope (SEM) and number of SA colony adhered to the coverslip of was counted. TSB: 
tryptic soy broth. 
it, namely the prevention of adhesion of SA to the skin and the 
removal of SA from the skin. Therefore, this FX cream is expect-
ed as a useful skin care agent for atopic dry skin colonized by 
SA.
3,4 Recently, we also found that AD-like lesions in DS-Nh of 
AD model mouse mice were significantly improved together 
with a decrease in number of SA detected from these lesions by 
treatment with the bamboo leaf extract cream having the anti- 
bacterial, viral and mycotic activity.
5 This improvement effect 
was also observed together with a decrease of the increased se-
rum IgE levels and IFN-g/IL-13 production in Con A-stimulated 
cultures of lymph node cells taken from these mice. From these 
results, this extract cream is suggested to have not only anti-
bacterial effects but also immunological effects as the thera-
peutic agent.
5 
It is well-known that SA discharges various toxins and enzymes 
that injure the skin, results in activation and proliferation of epi-
dermal keratinocytes, which produce and release IL-18. The IL-
18 is supposed to be involved in pathogenesis of AD, because IL-
18 induces the super Th1 cells producing and secreting IFN-g 
and IL-13.
6 Indeed, the serum IL-18 levels in patients with AD Ikezawa et al. Volume 2, Number 4, October 2010
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significantly correlated with skin scores of AD lesions, as shown 
Fig. 6-1.
7 From these lesions, SA is detected with high frequency 
and a correlationship is observed between eruption score and 
the number of SA detected, as above-mentioned. Also, there is a 
strong positive correlation between skin scores and serum IL-
18 levels in DS-Nh mice (P<0.0001, r=0.64) with AD-like lesions, 
in which SA is supposed to be a critical factor for the develop-
ment of AD lesions, as shown Fig. 6-2.
7,8 
DS-Nh mice develop AD-like legions when they are housed 
under conventional conditions, but develop skin legions with 
less severity and less frequency under specific pathogens free 
(SPF) conditions.
9 Furthermore, an increase of IL-18 produc-
tion from epidermal cells was observed in AD model mice in-
duced by subsequent topical application of SA products.
6 There-
fore, in order to clarify the role of IL-18 in the pathogenesis of 
AD, we measured IL-18 levels in the horny layer (i.e. horn IL-
18) by the method using tape stripping and ELISA, which has 
been already established for measurement of NGF level in the 
horny layer
10 and assessed the horn IL-18 level in relation to 
clinical severities and SA colonization on the involved skin of 
Control
A complete biofilm of SA was 
formed and the structure was 
maintained for 8 days 
(6.2×10
8 cfu/cm
2)
FX (0.2% 
farnesol + 5% xylitol)
The formed biofilm of SA 
disappeared 
(5.3×10
7 cfu/cm
2)
Human plasma: tryptic soy broth (TSB) : =1:1,  
SA (from AD, inoculated with 10
8 cfu/well), incubation:
at 37℃ for 48 hr
0.05% aminobenzylpenicillin (ABPC)
The formed biofilm was hardly dissolved (4.2×10
8 cfu/cm
2)
Fig. 3-2. FX dissolve the formed biofilm of SA.
3
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＊
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FX cream
Fig. 4. The treatment with FX cream improved significantly 4 items out of 5 items in AD lesions 2 weeks later, while the treatment with control cream improved only 
1 item of dryness/desquamation.
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AD patients. The horn proteins were collected via tape stripping 
from the horny layer of the skin in 61 AD patients and 40 healthy 
controls, and the horn IL-18 levels were measured using ELISA. 
Clinical severity, blood data and SA colonization of involved 
skin were also evaluated before and 4-8 weeks after treatment. 
The results showed that the horn IL-18 levels of skin lesions 
were significantly higher in AD patients than in healthy controls 
and correlated to SCORAD, serum IL-18, IgE, LDH, thymus and 
activation-regulated chemokine (TARC) and TEWL.
11 In the 
group of AD patients with IgE <1,500 IU/m, the horn IL-18 levels 
was significantly higher in patients whom SA was detected than 
in patients from whom SA was not.
11 From these results, SA col-
onization on the skin lesions is conceivable to contribute to the 
IL-18 production of epidermal keratinocytes especially in the 
group of AD patients with relatively low IgE production and the 
horn IL-18 levels seem to be associated with the severity of AD. 
It is interesting that DS-Nh mice pretreated with cyclophosph-
amide (Cy) developed more remarkable AD-like lesions with 
more number of SA colonies on the skin surface, in comparison 
with untreated ones.
12 The levels of IFN-g and IL-13 in the su-
pernatants of the lymph node cell cultures stimulated with SEB 
or ConA were increased remarkably in the Cy-treated mice, al-
though the serum levels of total IgE were not.
12 In this experi-
ment, we also revealed that Cy-treated mice, to which CD25+ 
CD4+ regulatory T cells taken from non-treated ones had been 
transferred, developed AD-like legions with less severity and 
less number of SA colonies on the skin surface.
12 Table simply 
shows the summary of these results. Therefore, it is presumed 
that CD25+CD4+ regulatory T cells might be involved in sup-
pression of super Th1 cells, which are induced by IL-18 and are 
involved in the development of AD-like lesions rather than IgE 
production. The efficient induction of CD25+CD4+ regulatory 
T cells may become new type of treatment for recalcitrant AD. 
Fig. 7 shows schematically the action mechanism of FoxP3+ 
Fig. 5.  Application of FX cream containing 0.2% farnesol and 5% xylitol to AD patients for 2 weeks decreased the number and rate of SA significantly when com-
pared with the number at the start and with placebo control treatment.
3 FX: cream containing 0.2% farnesol and 5% xylitol, CT: control treatment,
# the rate (%) of SA 
to total bacteria, N.S. : not significant, 
**P<0.05, 
***P<0.01.
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Fig. 6-1.  Comparison between serum levels of IL-18 and global skin scores in 
AD patients divided into 4 groups based on their disease severities.
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CD25+CD4+ regulatory T cells, which are conceivable to sup-
press the induction and exacerbation of AD-like lesions through 
the suppression of IFN-g/L-13 production of by FoxP3-CD25-
CD4+ super Th1 cells in DS-Nh of AD model mouse associated 
with SA colonization on the skin surface.
12-14
A ROLE OF NERVE GROWTH FACTOR (NGF) IN 
PATHOGENESIS AND BIOMARKER OF AD FROM THE 
QUANTITATIVE ANALYSIS OF NGF IN HORNY LAYER OF 
AD PATIENTS 
Nerve growth factor (NGF), which belongs to the neurotro-
phin family, is mainly produced and released by the basal kera-
tinocytes
15-19 and has diverse activity in the skin. Immunohis-
tochemistry of human skin shows that NGF is expressed in su-
prabasal keratinocytes and in basal keratinocytes.
18 Recently, 
neurogenic inflammation, including effect of neuropeptides 
such as substance P (SP) and NGF, has provided a new per-
spective in understanding the pathogenesis of AD.
20 Increasing 
evidence suggests that neurotrophins are supposed to be in-
volved in the neurogenic inflammation of AD and to be one of 
factors, which regulate development of AD.
21 It has been report-
ed that NGF levels of AD patients are measured in plasma,
16 
urine and saliva,
22 and the NGF level in plasma increases and 
correlates with the disease severity.
16 Furthermore, it has been 
also reported that expression of NGF increases in the AD le-
sions biopsied and relates to the aggravation of disease.
23 How-
ever, it is not so good method to measure the NGF level in the 
biopsied skin samples because it is invasive and cannot be 
done repeatedly. By the preliminary experiments, we estab-
lished a method using tape stripping and ELISA for measure-
ment of NGF in the horny layer (i.e. horn NGF), which is able to 
be accepted repeatedly in the same patient and then measured 
the horn NGF in AD patients by this method.
10 The results 
showed that the horn NGF level in the non-lesional skin of AD 
patients as well as in the lesional skin significantly increased, in 
comparison with the non-lesional skin of healthy subjects, as 
shown Fig. 8, being consistent with the previous histochemical 
findings that NGF expression in keratinocytes is increased in 
AD patients.
10 Then, we assessed a possible relationship be-
Fig. 7.  FoxP3
+CD25
+CD4
+ regulatory T cells are presumed to negatively regulate the induction and exercerbation of AD-like lesions through the suppression of IFNγ/
L-13 production of by FoxP3
-CD25
-CD4
+ super Th1 cells in DS-Nh of AD model mouse associated with SA colonization on the skin surface.
12,13  
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Table. Summary of results of Cy-pretreated and transferred experiments in DS-Nh mice
12  
Experiment 1 Experiment 2
Treated/Sensitized
recipient
Cy-untreated, 
TNCB-unsensitized
Cy-untreated, 
TNCB-sensitized
Cy-pretreated, 
TNCB-sensitized
Cy-pretreated, 
TNCB-sensitized
Cy-pretreated, 
TNCB-sensitized
Cy-pretreated, 
TNCB-sensitized
Transfer
of T cells
-/+ + ~ ++ +++ ~ ++++    
Increased
* PBS CD25- T (Te) CD25
+ T (Treg)
AD-like lesion score
-/+ + ~ ++ + ~ ++
Not increased
+++ ~ ++++ +++ ~ ++++
+ ~ ++
Decresed
*
Serum IgE level
Number of SA clonies
-/+ + ~ ++ +++ ~ ++++
Increased
** +++ ~ ++++ +++ ~ ++++
+ ~ ++
Dcreased
**
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tween the horn NGF level and the severity of itch and AD, and 
also examined effect of treatment on the horn NGF level. The 
positive correlations were observed between horn NGF level 
and itch severity, eruption score such as erythema, scale/xero-
sis and total skin score on the skin lesions measured, eosino-
phil count and serum LDH level, but were not between horn 
NGF level and skin scores of papule, erosion/crust and licheni-
fication on the skin lesions measured and serum IgE level.
10 The 
horn NGF level decreased significantly after treatment, which 
correlated with the decrease in itch severity, skin scores (ery-
thema, papule, scale/xerosis, lichenification and total skin 
score) on the measured skin lesions, serum LDH level, and es-
pecially eosinophil count.
10 These findings indicate that the 
horn NGF level reflects to some extent the severity of itch, erup-
tions, and laboratory data. The level of horn NGF had de-
creased significantly not only at 4 weeks, but also at 2 weeks af-
ter beginning treatment.10 Considering the fact that the turn-
over of the horny layer is approximately 14 days, it is presumed 
that epidermal NGF production is suppressed immediately af-
ter beginning treatment. Also, a significant decrease in NGF 
level was observed not only in the group treated with olopata-
dine and topical steroid, but also in the group treated with olo-
patadine alone, as shown Fig. 9. How olopatadine suppresses 
the increase of horn NGF levels induced in AD patients? It has 
been reported that histamine enhances NGF production of hu-
man keratinocyte through the stimulation of H1 receptors.
24 
Therefore, H1-antagtonist including olopatadine is conceivable 
to suppress the increase of horn NGF level by inhibiting the en-
hancement of NGF production by keratinocyte stimulated with 
histamine. Also, we have already reported that olopatadine 
suppresses the increase of SP levels in the skin lesions induced 
by the repeated application of 2,4,6-trinitrochlorbenzane in DS-
Nh of atopic model mouse.
25 In AD patients, too, it has been re-
ported that olopatadine significantly decreased the serum SP 
level because of down-modulatory effect on tachykinin re-
lease.
26 Other studies have also shown that whereas NGF stim-
ulates the synthesis and releases of SP in the central and pe-
ripheral nervous system, SP induces NGF synthesis via cytok-
ines, too.
27,28 These results suggest that the activations of NGF 
and SP are interdependent. Moreover, in studies of BALB/c 
mice with chronic contact hypersensitivity induced by oxazolo-
ne, it has been reported that oral administration of olopatadine 
suppressed the production of NGF and cytokines such as IL-4, 
IL-1B, IL-6 and GM-CSF in the affected ear tissues, unlike other 
histamine H1 receptor antagonists.
29-31 From these results, olo-
patadine is suggested to exerts its effect on AD not only by anti-
histamine effect but also by suppressing the production of NGF 
and SP. Taken all together, the horn NGF level is presumed to be 
able to serve as a marker to evaluate the clinical conditions of 
AD and the immediate effect of treatment because it can reflect 
the severity of itch and eruptions in AD. Therefore, quantifica-
tion of NGF in the samples collected directly from the horny 
layer appears to be useful in assessing the severity of AD and 
the therapeutic effects on AD. 
SEMAPHORIN 3A (SEMA3A) ALLEVIATES SKIN LESIONS 
AND SCRATCHING BEHAVIOR IN NC/NGA, MODEL MICE 
OF AD
Topical steroids and antihistamines are generally used for the 
treatment of AD. However, these treatments are not effective 
sufficiently for the recalcitrant AD with severe itching followed 
by uncontrollable scratching. In AD patients, the C-fiber in the 
epidermis increases and sprouts with the increase of horn NGF 
levels, inducing hypersensitivity to itching, which is considered 
Fig. 8.  NGF levels in the horny proteins.
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to aggravate the disease, as above-mentioned. Semaphorin 3A 
(Sema3A), an axon guidance molecule, is a potent inhibitor of 
neurite outgrowth of sensory neurons by exerting the plexin-
A1-4 and neuropilin-1 (NRP-1) of its receptors.
32,33 Fig. 10 shows 
semaphorin family and its receptors. Sema3A may become ef-
fective drug against refractory itching skin diseases such as AD 
in future by suppressing the hypersensitivity to itching through 
inhibition of the extension and sprout of C-fiber in the epider-
mis. From this point of view, we administered the recombinant 
Sema3A intracutaneously into the AD-like skin lesions of NC/
Nga mice, an animal model of AD, in order to investigate the ef-
fect of Sema3A on AD. Sema3A improved significantly AD-like 
lesions of NC/Nga, AD model mouse (Fig. 11-1), and the im-
provement effect was a dose-dependent manner (Fig. 11-2) and 
was presumed to be brought through the suppression of scratch-
ing accompanied with itching, because Sema3A suppressed 
significantly the scratching behavior of NC/Nga mice (Fig. 11-
3). Histopathological examinations revealed an improvement 
of acanthosis, a remarkable reduction in the density of invasive 
nerve fibers, and a decrease of the inflammatory infiltrate in-
cluding mast cells and CD4+ T cells and the interleukin-4 (IL-4) 
production in the Sema3A-injected area of AD-like lesions.
34 
The improvement effect was associated with the suppression of 
scratching behavior in Sema3A-treated animals. These findings 
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indicate for the first time that Sema3A in vivo remarkably im-
proves AD-like lesions in NC/Nga mice, an animal model of 
AD. This is the first trial for a potential clinical application of 
semaphorins. Sema3A acts locally and exerts a continuous ef-
fect for a while even after discontinuation. But this effect of Se-
ma3A on scratching was reversible, because the decrease in 
scratching behavior returned to the basal levels immediately af-
ter the discontinuation of Sema3A, followed by recurrence of 
lesions, as shown in Fig. 11-1, 2, 3. These results suggest that 
scratching behavior aggravates AD and Sema3A can ameliorate 
the symptoms of AD by interrupting the itch-scratch cycle, which 
is an important cause of aggravation and chronicity of AD. Re-
cently, there has been an interesting report that epidermal Se-
ma3A levels were decreased in patients with AD compared 
with healthy volunteers, concomitant with the increase of epi-
dermal nerve densities.
35 This result shows that there is a good 
correlation between epidermal innervation and Sema3A levels, 
which may provide an important evidence for the therapeutic 
claim against itching. Many drugs have been developed for the 
treatment of AD. However there is no treatment other than Se-
ma3A which targets the invasive nerve fibers in the epidermis. 
Therefore, Sema3A is expected to become an effective and use-
ful drug for AD patients with severe recalcitrant itching, which 
is resistant to anti-histamine drugs of H1-blocker and anti-in-
flammatory steroid ointment. 
Recently, transient receptor potential vanilloid receptor sub-
type 1 (TRPV1) and capsaicin are noticed as topics regarding 
treatment of itching. The generally accepted concept for the 
therapeutic application of capsaicin to mitigate itch is based on 
desensitizing effect of this vanilloid. However, the most notori-
ous clinical limitation of capsaicin application is supposed to 
be acute excitation of the sensory C-afferents, which is induced 
by the TRPV1 and results in a remarkable “hot painful burning” 
sensation.
36 Does reduction in innervation density of intraepi-
dermal nerve fibers by the local application of Sema3A cause 
such a sensation? In our experiments regarding the effects of 
Sema3A on AD-like lesions, no apparent abnormalities in anti-
nociceptive response as well as in general symptoms were ob-
served on local treatment with Sema3A. Answering above ques-
tions should be required before therapeutic attempts in hu-
man. Sema3A, when intracutaneously administered repeated-
ly, significantly improved AD lesions on day 2 or 3 after the start 
of the injections, as shown in Fig. 11-3. Recent studies indicate 
that semaphorins play diverse roles unrelated to axon guid-
ance, including organogenesis, vascularization and angiogene-
sis.
37-39 In particular, attention has been given to the fact that 
several semaphorins play critical roles in the immune sys-
tem.
40,41 It has been reported that Sema3A,
41,42 Sema3C,
43 Se-
ma4A,
44 Sema4D
42,44-50 and Sema7A
51 function in various phas-
es of immune system. From these recent knowledges and the 
above-mentioned histopathological findings in our experi-
ments, the effects of Sema3A on AD-like lesions are conceiv-
able to involve other mechanisms such as regulation of the im-
mune and vascular systems, in addition to the suppression of 
the invasive sensory neurons in the epidermis. In addition, Se-
ma3A and NRP-1 of its receptors expressed in human keratino-
Fig. 12.  Pathomechanism of itch and action mechanism of Sema3A on itching of AD lesions: Sema3A has not only the neurological activity, which inhibits the intra-
epidermal extension of peripheral nerve, but also the immunological anti-inflammatory activity, and is expected as a new type of drug effective for refractory AD pa-
tients who are resistant to existing drugs.Ikezawa et al. Volume 2, Number 4, October 2010
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cytes
52 may be relevant to the above-mentioned suppressive ef-
fect of Sema3A on acanthosis observed in our present experi-
ment. Also Sema3A and NRP-1 of its receptors expressed in 
dendritic cells and T cells
53,54 may be relevant to the immuno-
logical effect of Sema3A such as suppression of CD4+ T cells in-
filtration and IL-4 production observed in the AD-like lesions 
in NC/Nga mice treated with Sema3A, as above-mentioned. 
In 2005, Takano et al., reported that anti-NGF antibodies in-
hibited the development of skin lesions and epidermal inner-
vation in the NC/Nga of AD model mouse, accompanied with 
the reduction of scratching.
55,56 Thus Sema3A may function as 
well as anti-NGF antibodies may act on the both of immuno-
logical and neurological mechanisms. However, the combina-
tion therapy of Sema3A with anti-NGF antibody may not be 
justified for AD, because NGF is known to increase the expres-
sion levels of NRP-1
57 and to augment the effect of Sema3A to 
induce axon repulsion (or growth cone collapse) of dorsal root 
ganglia neurons.
58 Further studies should be required to eluci-
date the mechanism of action of Sema3A on AD. Fig. 12 shows 
schematically the pathomechanism of itch and action mecha-
nism of Sema3A on itching of AD lesions. Sema3A has not only 
the neurological activity, which inhibits the intraepidermal ex-
tension of peripheral nerve, but also the immunological anti-
inflammatory activity, and is expected as a new type of drug ef-
fective for refractory AD patients who are resistant to existing 
drugs. It is possible that Sema3A is also widely effective for se-
vere itching skin diseases other than AD in which the itch-
scratch cycle is involved. 
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